Ultragenyx Pharma (RARE) Tops Q4 EPS by 10c

Ultragenyx Pharma (NASDAQ: RARE) reported Q4 EPS of ($1.89), $0.10 better than the analyst estimate of ($1.99).

For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• Nucor projects Q3 2026 earnings above prior year, below estimates
• FDA approves Ultragenyx gene therapy for rare childhood disease